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Spatial relationship of 2-deoxy-2-[18F]-
fluoro-D-glucose positron emission
tomography and magnetic resonance
diffusion imaging metrics in cervical cancer
John M. Floberg1* , Kathryn J. Fowler2,3, Dominique Fuser2, Todd A. DeWees4, Farrokh Dehdashti2,3,
Barry A. Siegel2,3, Richard L. Wahl1,2,3, Julie K. Schwarz1,3,5 and Perry W. Grigsby1,2,3
Abstract
Background: This study investigated the spatial relationship of 2-deoxy-2-[18F]-fluoro-D-glucose positron emission
tomography ([18F]FDG-PET) standardized uptake values (SUVs) and apparent diffusion coefficients (ADCs) derived
from magnetic resonance (MR) diffusion imaging on a voxel level using simultaneously acquired PET/MR data.
We performed an institutional retrospective analysis of patients with newly diagnosed cervical cancer who received
a pre-treatment simultaneously acquired [18F]FDG-PET/MR. Voxel SUV and ADC values, and global tumor metrics
including maximum SUV (SUVmax), mean ADC (ADCmean), and mean tumor-to-muscle ADC ratio (ADCT/M) were
compared. The impacts of histology, grade, and tumor volume on the voxel SUV to ADC relationship were also
evaluated. The potential prognostic value of the voxel SUV/ADC relationship was evaluated in an exploratory
analysis using Kaplan-Meier/log-rank and univariate Cox analysis.
Results: Seventeen patients with PET/MR scans were identified. There was a significant inverse correlation between
SUVmax and ADCmean, and SUVmax and ADCT/M. In the voxelwise analysis, squamous cell carcinomas (SCCAs) and
poorly differentiated tumors showed a consistent significant inverse correlation between voxel SUV and ADC values;
adenocarcinomas (AdenoCAs) and well/moderately differentiated tumors did not. The strength of the voxel SUV/
ADC correlation varied with metabolic tumor volume (MTV). On log-rank analysis, the correlation between voxel
SUV/ADC values was prognostic of disease-free survival (DFS).
Conclusions: In this hypothesis-generating study, a consistent inverse correlation between voxel SUV and ADC
values was seen in SCCAs and poorly differentiated tumors. On univariate statistical analysis, correlation between
voxel SUV and ADC values was prognostic for DFS.
Keywords: PET/MRI, Multimodal imaging, Diffusion imaging, Cervical cancer, Imaging biomarkers
Background
Despite advances in both prevention of cervical can-
cer with HPV vaccination and screening for
pre-malignant and early stage disease using the Papni-
colaou test, deaths from cervical cancer have
remained steady in the USA since the mid-2000s [1].
Worldwide, cervical cancer is the fourth leading cause
of cancer deaths [2]. A number of prognostic imaging
markers have been developed in cervical cancer that can
identify patients at high risk for disease progression, recur-
rence, and death. Imaging markers derived from
2-deoxy-2-[18F]-fluoro-D-glucose positron emission tom-
ography ([18F]FDG-PET), such as the maximum standard-
ized uptake value (SUVmax), are the most studied and best
established [3–6]. More recently, magnetic resonance
imaging (MRI)-derived markers, particularly diffusion
metrics, such as the apparent diffusion coefficient of water
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(ADC), have been studied as additional prognostic im-
aging markers for cervical cancer [7–11].
To date, tumor response on post-treatment
[18F]FDG-PET imaging has been shown to be one of the
most powerful prognostic imaging markers in cer-
vical cancer [12]. Although this is useful as a prog-
nostic tool, it cannot be used to guide treatment
decisions prospectively. A more robust pre-therapy
marker would therefore be valuable. Greater under-
standing of the underlying biology of tumors at high
risk for recurrence is also needed, and multimodal
imaging markers, for example, utilizing both
[18F]FDG-PET and MRI data, might provide insight
into the physiologic and biologic properties of
aggressive tumors.
The spatial relationship between [18F]FDG-PET met-
rics and MRI-derived diffusion metrics, namely ADC
values, is not yet clear. The relationship of whole tumor
imaging metrics, such as SUVmax and minimum ADC
(ADCmin), has previously been studied in cervical cancer
as well as several other cancers, with a suggestion that
SUV and ADC metrics are inversely correlated [13–20].
Previous work has also shown that qualitatively, re-
gions of intense [18F]FDG uptake within primary cer-
vical tumors correlate with regions with lower ADC
values [21]. Simultaneously acquired PET/MRI allows
for comparison of PET- and MRI-derived imaging
markers on a fine spatial scale, for example, on the
voxel level if the matrices of PET and MRI images
are made the same size. Such a comparison would
provide better understanding of the relationship
between these imaging markers. The relationship be-
tween these metrics in cancers with different histolo-
gies, namely squamous cell carcinoma (SCCA) and
adenocarcinoma (AdenoCA), and grades will also be
important to establish as prior work has shown that
histology and differentiation affect [18F]FDG uptake
[22]. The relationship between SUV and ADC may
also yield a more robust prognostic imaging marker
than can be obtained with either modality alone.
The primary purpose of this study was to compare
pre-treatment [18F]FDG-PET SUV and MRI ADC values
on a voxel-by-voxel basis in primary cervical cancer
tumors in patients with pre-treatment simultaneous
PET/MR scans. Global metrics, such as the SUVmax and
the mean ADC (ADCmean), were also compared, and the
relationship between SUV and ADC values was com-
pared between different histologies and different grade
tumors. The impact of tumor volume on the voxel SUV
to ADC relationship was also evaluated. Finally, the
ability of SUV and ADC metrics, and the strength of the
correlation between voxel SUV and ADC, to predict
disease-free survival (DFS) was investigated as an ex-
ploratory analysis.
Methods
Patients
This retrospective study using existing imaging data and
medical records was conducted with institutional review
board approval with a waiver of consent. Some of the
patients included in this study were enrolled on pro-
spective imaging trials for which they provided written
consent; the results reported here are not related to the
aims of those studies. Patients from our institution with
biopsy proven cervical cancer with pre-treatment simul-
taneously acquired PET/MR examinations obtained
between October 2011 and June 2016 were identified.
This included patients subsequently treated with defini-
tive chemoradiation and patients subsequently treated
with surgery. Patient clinical and demographic charac-
teristics were obtained through review of the medical
record. Patient outcome data, namely disease status,
time to recurrence, and time to death, were obtained
through review of the medical record and publicly
available records.
Patient preparation and image acquisition
Patients fasted for at least 4 h, and blood glucose was re-
quired to be less than 11.1 mmol/L prior to [18F]FDG
injection. The radiotracer was administered intraven-
ously with a mean activity of 512.82 MBq, 6.80 MBq/kg
(range 218.3–710.4 MBq, 2.91–9.07 MBq/kg). The ma-
jority of patients (10/17, 58.8%) had Foley catheters
placed prior to radiotracer injection. Eleven patients in-
cluded in this study were also enrolled on a PET/MRI
optimization study, in which they first underwent a
PET/CT according to our standard institutional proto-
col, immediately followed by a PET/MRI. In these
patients, the average time from the radiotracer injection
to the start of the PET/MR acquisition was 135 min
(range 103–171 min).
For PET/MRI scanning, all imaging was performed on
a Siemens Biograph mMR integrated PET/MRI scanner
(Siemens Medical Solutions USA, Inc.). Whole-body
static PET images were acquired at multiple bed
positions for 3–4 min per position. Images were recon-
structed using an ordinary Poisson-ordered subset
expectation-maximization algorithm (OP-OSEM) to a
voxel size of 4.17 × 4.17 × 2.03 mm. Attenuation correc-
tion was performed using the MRI data, and scatter cor-
rection was performed using the system’s model-based
algorithm.
MR images were acquired simultaneously with the PET
data. MR sequences included a Dixon sequence for PET
attenuation correction, a half-Fourier acquired single-shot
turbo spin-echo (HASTE) sequence for localization and
anatomical overview, a T2 high-resolution isotropic fast
spin-echo sequence (SPACE) to characterize lesion
morphology, and a contrast-enhanced dynamic 3D T1 fat
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suppression sequence. Diffusion-weighted images were ac-
quired using an echo-planar diffusion imaging sequence
with an axial acquisition, slice thickness of 5 mm, in plane
resolution of 3.4 mm, and b values of either 50–500–1000,
50–500–800, or 50–400–600. ADC maps were produced
by the scanner from the diffusion-weighted images.
Image analysis
All image analysis was performed on a MIM Vista work-
station (MIM Software Inc.). [18F]FDG-PET images were
resampled to the ADC image matrix, such that the vox-
els between the modalities matched. We focused our
analysis on regions with diffusion restriction and high
[18F]FDG avidity. Therefore, gross tumor volumes of
interest (VOIs) were manually defined on the ADC im-
ages by one of the authors (JMF) to encompass the
hypointense, diffusion-restricted region of the tumor,
using the T2 and [18F]FDG-PET images to help verify
the location of the tumor, according to our institutional
practice [23, 24]. In cases where there was no discern-
able hypointense tumor on the ADC image, PET images
were segmented to define the tumor based on a thresh-
old equal to 40% of the SUVmax [25]; this was the case
in three of the AdenoCAs. Global tumor PET imaging
metrics obtained included the SUVmax, metabolic tumor
volume (MTV) defined with a 40% of the SUVmax thresh-
old, mean SUV (SUVmean) determined within the MTV,
total lesion glycolysis (TLG) obtained by multiplying the
MTV by the SUVmean, and the SUVmean normalized by
the average SUV of adjacent gluteal muscle (SUVT/M).
Global tumor MRI metrics included the ADC tumor vol-
ume (ADCvol), ADCmin, mean ADC (ADCmean), and the
ratio of the mean tumor ADC to the mean ADC of the
adjacent gluteal muscle (ADCT/M).
Primary tumor SUVmax, SUVmean, and SUVT/M were
compared to the ADCmean, ADCT/M, and ADCmin of the
tumor. SUV and ADC values were also compared on a
voxel-by-voxel basis within each tumor. The global
tumor metrics outlined above and voxel-by-voxel correl-
ation between SUV and ADC were also compared
between SCCAs and AdenoCAs. Finally, the impact on
tumor grade (poorly vs. well/moderately differentiated)
and tumor volume (using MTV) on the relationship of
voxel SUV and ADC values was evaluated. The author
performing the image analysis (JMF) was blinded to pa-
tient outcomes at the time of image analysis.
Statistics
Correlation between global tumor SUV and ADC values
(e.g., SUVmax and ADCmean, SUVmax, and ADCT/M), and
between voxel SUV and ADC values, was determined
using the Pearson correlation coefficient. The correlation
between the voxel SUV/ADC relationship and MTV was
also determined using the Pearson correlation coefficient.
The statistical significance of the correlations was deter-
mined using two-sided t statistics. Imaging metrics from
SCCAs and AdenoCAs, and poorly and well/moderately
differentiated tumors, were compared using the two-sided
Mann-Whitney U test. The prognostic value of the
correlation between voxel SUV and ADC values (using
Pearson’s r), as well as the SUVmax, MTV, ADCmean, and
ADCT/M were determined using Kaplan-Meier and
log-rank analysis, and Cox univariate proportional hazards
analysis for disease-free survival (DFS). This analysis was
performed using SPSS (IBM Analytics). Variables were
treated as categorical for both the Cox proportional
hazards and the log-rank analysis, dichotomized by the
median for each imaging metric.
Results
Patient characteristics
A total of 17 patients were identified, 9 (52.9%) with
SCCA, 6 (35.3%) with AdenoCA, and 1 (5.9%) each of
small cell carcinoma and adenosquamous carcinoma.
The majority of patients (14, 82.4%) were treated with
definitive chemoradiation therapy. Median follow-up for
the cohort was 23.9 months. The 2 year DFS and OS
were 76.5 and 82.4%, respectively. Patient characteristics
are summarized in Table 1.
Global tumor metrics
Global tumor imaging metrics assessed included the
PET metrics of SUVmax, MTV, and TLG, and the MRI
diffusion metrics of ADCmin, ADCmean, ADCT/M, and
ADCvol. The average values of these metrics were com-
pared between SCCA and AdenoCA tumors (Table 2).
There was not a statistically significant difference be-
tween any of these values between SCCAs and Adeno-
CAs in this patient cohort.
The correlation between SUVmax and ADCmean, and
SUVmax and ADCT/M were evaluated for all tumors
(Fig. 1a, b). There was a significant inverse correlation
between SUVmax and both of these ADC metrics. The
correlation between SUVmax and ADCmin was also eval-
uated and was non-significant (r = − 0.43, p = 0.08).
There was also a significant correlation between SUV-
mean and ADCmean (p = 0.007) and between SUVmean and
ADCT/M (p = 0.008). There was no significant correlation
between SUVT/M and either ADCmean (p = 0.08) or
ADCT/M (p = 0.06) (Additional file 1: Figure S1). The
correlation between SUVmax and ADCmean was also
evaluated for SCCAs and AdenoCAs. There was an
inverse correlation between these metrics for both his-
tologies, which remained significant in AdenoCAs but
did not meet the threshold for significance in SCCAs
(Fig. 1c, d). The inverse correlation between SUVmean
and ADCmean, and SUVmean and ADCT/M, did not main-
tain significance when dividing tumors into AdenoCAs
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(p = 0.07 and 0.09, respectively) and SCCAs (p = 0.15
and 0.21, respectively).
Voxelwise comparison
Individual voxel SUV and ADC values were compared
for each primary tumor. A linear least-squares fit was
performed for each tumor, and the slope and Pearson’s
correlation coefficients were determined. Example
patients with SCCA and AdenoCA tumors and the voxel
comparisons of ADC and SUV are shown in Fig. 2.
SCCA tumors appeared dark on the ADC images, corre-
sponding to areas of intense [18F]FDG uptake, and
voxel-by-voxel comparison of ADC and SUV showed an
inverse correlation in this example (Fig. 2a, b). In con-
trast, while some AdenoCAs showed this correlation,
others appeared heterogeneous on the ADC images, and
in the example patient, voxel-by-voxel comparison of
ADC and SUV revealed little correlation (Fig. 2c, d).
When all patients with SCCAs were grouped together,
all but two patients showed a strong inverse relationship
between ADCs and SUVs; the two outliers still had a
significant correlation between SUV and ADC but with
a less steep slope (Fig. 3a). When all AdenoCAs were
grouped together, one tumor showed a strong inverse
relationship between ADC and SUV, but other tumors
showed little to no correlation (Fig. 3b).
We then compared the Pearson correlation coeffi-
cients of the SCCAs and AdenoCAs. The adenosqua-
mous cancer and small cell cancer were therefore
excluded from this analysis. All of the SCCAs showed a
statistically significant inverse correlation between SUV
and ADC, with a mean Pearson’s r = − 0.35. In contrast,
though there were three AdenoCAs with a statistically
significant inverse correlation between SUV and ADC,
there was a wide spread of Pearson’s correlation coeffi-
cients, with a mean r = − 0.068. The difference in the
mean Pearson’s correlation coefficients between SCCAs
and AdenoCAs did not meet statistical significance in
this small patient cohort with a broad range of correl-
ation coefficients in the AdenoCAs (p = 0.27, Fig. 3c).
We also compared the Pearson correlation coefficients
between poorly and well/moderately differentiated tu-
mors. All but one poorly differentiated tumor showed a
statistically significant inverse correlation between voxel
SUV and ADC with a mean r = − 0.36, and 4/6 well/
moderately differentiated tumors had a statistically sig-
nificant inverse correlation between voxel SUV and
ADC with a mean r = − 0.006 (Fig. 3d). The difference in
the mean Pearson correlation coefficient between poorly
and well/moderately differentiated tumors did reach
statistical significance (p = 0.015). Notably, 4/6 of the
AdenoCAs were also well/moderately differentiated, and
7/9 of the SCCAs were poorly differentiated.
Finally, we investigated the impact of tumor volume
on the voxel SUV/ADC correlation. When all tumors
are considered, there is a significant inverse correlation
between the voxel SUV/ADC relationship and MTV
(Fig. 3e, r = − 0.49, p = 0.046). However, three of the
small tumors with no inverse correlation between voxel
SUV and ADC were AdenoCAs. Considering SCCAs
Table 1 Characteristics of the patient cohort
Characteristic No. of patients (%)
Histology
SCCA 9 (52.9%)
AdenoCa 6 (35.3%)
Small cell 1 (5.9%)
Adenosquamous 1 (5.9%)
Grade
Well differentiated 3 (17.6%)
Moderately differentiated 3 (17.6%)
Poorly differentiated 11 (64.7%)
Treatment modality
Surgery only 3 (17.6%)
Chemo-RT 14 (82.4%)
FIGO stage
IA 0 (0%)
IB1 4 (23.5%)
IB2 7 (41.2%)
IIA 1 (5.9%)
IIB 0 (0%)
IIIA 1 (5.9%)
IIIB 3 (17.6%)
IVA 0 (0%)
IVB 1 (5.9%)
Nodal involvement
None 7 (41.2%)
Pelvic 7 (41.2%)
Para-aortic 2 (11.8%)
Supraclavicular 1 (5.9%)
Table 2 Comparison of global tumor imaging metrics between
SCCAs and AdenoCAs
SCCAs AdenoCAs p value
ADCmean 958.9 1198.5 0.18
ADCT/M 0.77 0.95 0.11
ADCmin 402.6 331.5 0.27
SUVmax 13.2 11.1 0.86
MTV 41.12 24.7 0.33
TLG 280.9 258.9 0.61
ADCvol 47.16 49.93 0.61
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and AdenoCAs separately, there is still a significant in-
verse correlation between MTV and the voxel SUV/
ADC relationship in AdenoCAs (r = − 0.84, p = 0.04), but
not in SCCAs (r = − 0.39, p = 0.30).
PET and diffusion MR imaging metrics and patient
outcomes
Univariate statistical analysis of the prognostic value of
the correlation between voxel SUV and ADC values was
performed as an exploratory analysis. The prognostic
value of established PET and MRI imaging metrics was
also evaluated in this cohort for comparison. Given the
small sample size, analysis of other known clinical prog-
nostic factors, such as FIGO stage and lymph node
status, was not performed. Multivariate analysis was not
performed because of the small number of patients
included in this study. Univariate Cox proportional
hazards and Kaplan-Meier/log-rank analyses was per-
formed dichotomizing variables by the median (Table 3).
Only the Pearson’s correlation coefficient significantly
Fig. 1 Comparison of the global tumor metrics of SUVmax and ADCmean (a) and SUVmax and ADCT/M (b) for all tumors. When SCCAs and
AdenoCAs are considered separately, there is still a significant inverse correlation between SUVmax and ADCmean for AdenoCAs (c), and though
there is an inverse correlation in SCCAs, it does not meet significance (d)
Fig. 2 Representative SCCA tumor (a) and the corresponding plot comparing the ADC and SUV of each voxel from the primary tumor (b). A
representative AdenoCA tumor (c) and its corresponding plot comparing ADC and SUV (d) are also shown. Most SCCA tumors showed a correlation
between voxel ADC and SUV values, whereas most of the AdenoCAs did not
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stratified patients for DFS by the log-rank test (p =
0.026), with a stronger correlation between SUV and
ADC portending a worse prognosis (Table 3, Fig. 4).
No variables reached significance on the univariate
Cox analysis. No imaging metrics were significantly
prognostic for overall survival by either Cox
proportional hazards analysis or Kaplan-Meier/log-rank
analysis (Additional file 1: Table S1).
Discussion
[18F]FDG-PET is an established prognostic imaging
marker in cervical cancer, and more recently
diffusion-weighted MRI has also emerged as a potential
imaging marker [3–8, 10, 12, 26]. The relationship
between global tumor PET and diffusion MR imaging
metrics, such as SUVmax and the ADCmin, has previ-
ously been evaluated in cervical cancer, with data
suggesting that these metrics are related [13, 17, 27].
The spatial relationship between ADC and SUV has
qualitatively been described as well [21]. However,
little is known about quantifying the spatial relation-
ship between SUV and ADC, or the prognostic
significance of the relationship between these metrics.
Furthermore, there are limited data addressing the
significance of histology and tumor grade on the
Fig. 3 The voxel ADC vs. SUV comparisons for all SCCA tumors (a) and all AdenoCA tumors (b). Each point represents a single voxel, and all
voxels from all tumors are displayed together. For the SCCAs (a), in the majority of tumors, there is a steeper SUV vs. ADC slope (blue); for two
tumors, the slope is not as steep, but there is still a correlation (red). For the AdenoCAs (b), one tumor has a steep SUV vs. ADC slope (blue), but
voxels from the rest of the tumors are more erratically scattered (red). When the correlation between ADC and SUV, as measured by Pearson’s r, is
compared between SCCAs and AdenoCAs, there is a consistent inverse correlation between these values in SCCAs, but not AdenoCAs (c). Poorly
differentiated tumors have a significantly greater inverse correlation between voxel SUV and ADC compared to well/moderately differentiated tumors
(d). The correlation between voxel SUV and ADC varies with MTV, though this relationship is primarily driven by the AdenoCAs (e)
Table 3 Univariate Cox proportional hazards analysis and log-rank
analysis for DFS for the imaging metrics investigated. Variables
were treated as categorical, dichotomized by the median for each
imaging metric
Variable Cox proportional hazards analysis Log-rank
ADCmean 1.212 [0.270–5.439] p = 0.80 p = 0.80
ADCT/M 3.12 [0.60–16.11] p = 0.18 p = 0.16
SUVmax 1.312 [0.292–5.885] p = 0.72 p = 0.72
MTV 3.637 [0.722–18.31] p = 0.12 p = 0.095
Pearson’s r 7.925 [0.934–67.23] p = 0.058 p = 0.026†
†p ≤ 0.05
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relationship between these imaging metrics in cervical
cancer [27].
With regard to global tumor metrics from
[18F]FDG-PET and ADC images, our data showed a
correlation between SUVmax and ADCmean, and SUVmax
and ADCT/M when all tumors were considered (Fig. 1).
The same is true with SUVmean and ADCmean and
ADCT/M (Additional file 1: Figure S1). Results from
prior studies have been heterogeneous, with some show-
ing a relationship between SUV and ADCs, and others
showing mixed result or no correlation between these
values [13, 14, 16, 27]. Interestingly, in our patient co-
hort, we found a strong correlation between the SUVmax
and the ADCmean and ADCT/M, as opposed to the
ADCmin which has previously been reported [13]. Nor-
malizing tumor ADC to surrounding musculature has
been reported for other disease sites in the pelvis [28],
and may warrant further investigation for cervical can-
cer, as it may help minimize variability in ADCs between
scans. In the case of our study, it may have helped offset
differences in ADCs from different b values used in the
scans included.
We also investigated how histology impacts global
tumor metrics. In our patient cohort, there was no
significant difference between SCCAs and AdenoCAs in
the average values for the diffusion metrics (ADCmean,
ADCT/M, ADCmin, and ADCvol) or the PET metrics in-
vestigated (SUVmax, SUVmean, MTV, and TLG). With re-
gard to the relationship between global tumor PET and
ADC metrics, in our cohort, there was a significant in-
verse correlation between SUVmax and ADCmean in
AdenoCAs, and though there was an inverse correlation
between these metrics in SCCAs, it did not meet the
threshold for significance (Fig. 1c, d).
Prior works investigating how histology impacts PET
and MRI metrics have yielded diverse results. Differ-
ences in [18F]FDG-PET imaging metrics between
different cervical cancer histologies have previously been
reported in a large series, which showed that on average,
SCCAs have a greater SUVmax than non-SCCAs [22].
Similar findings have been reported for other cancer
types (e.g., non-small cell lung cancer) [29, 30]. This was
not seen in our small patient cohort. Prior studies have
reported conflicting results regarding differences in
ADC values between SCCAs and AdenoCAs, but the
largest reported series supports that SCCAs have lower
ADC values than AdenoCAs [14, 26, 31]. In our series,
the average ADCmean and the ADCT/M are lower in
SCCAs compared to AdenoCAs, though this did not
reach statistical significance (Table 2). With regard to
correlation between global tumor SUV and ADC met-
rics, a previous study has reported an inverse correlation
between relative SUVmax (defined as SUVmax/SUVmean)
and a relative ADCmin (ADCmin/ADCmean) in AdenoCAs
and adenosquamos cancers, but not SCCAs [14, 32].
Similarly, our data show an inverse correlation between
SUVmax and ADCmean in AdenoCAs, but not SCCAs,
though the strength of these relationships could change
with a larger patient cohort.
Simultaneous acquisition of PET and MRI has the ad-
vantage of accurate image co-registration and has
allowed us to compare SUV and ADC on a voxel level.
In this study, we have performed this comparison in re-
gions of restricted diffusion and high [18F]FDG avidity.
To our knowledge, this is the first work investigating
this relationship in primary cervical cancer tumors. Our
data showed a consistent and significant inverse correl-
ation between voxel SUV and ADC values in all SCCAs.
However, only three of the AdenoCAs showed a statisti-
cally significant inverse correlation between voxel ADC
and SUV, and three did not (Figs. 2 and 3). There was
not a significant difference in the mean Pearson’s r of
the SUV/ADC correlation between the SCCAs and the
AdenoCAs. There was a significant difference between
Fig. 4 Kaplan-Meier curves for DFS with patients stratified by the median Pearson’s r for the correlation between voxel ADC and SUV (a) and the
median MTV (b). Tumors with a stronger inverse correlation between ADC and SUV show poorer disease outcomes
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the voxel SUV/ADC correlation in poorly differentiated
tumors compared to well/moderately differentiated tu-
mors (Fig. 3d). It is important to note that 7/9 of the
poorly differentiated tumors were SCCAs, and 4/6 of the
well/moderately differentiated tumors were AdenoCAs.
Given the overlap between grade and histology, the indi-
vidual impacts of histology and tumor grade cannot be
determined in this small patient cohort. The difference
seen between these histologies and tumor grades may
reflect some underlying physiologic or biologic differ-
ence in these tumors. It may reflect decreased cell dens-
ity, and therefore less restricted diffusion, in the
AdenoCAs and well/moderately differentiated tumors
[26, 31]. This would be consistent with the higher
ADCmean and ADCT/M values seen in AdenoCAs as well.
However, different degrees of correlation between voxel
SUV and ADCs are seen in both SCCAs and AdenoCAs
and within the different tumor grades, and a more
complete, and possibly alternative, underlying mechan-
ism should be sought.
We also found a significant correlation between MTV
and the voxel SUV/ADC relationship (Fig. 3e). This may
imply that volume averaging effects or other
volume-dependent effects impact the relationship be-
tween voxel SUV and ADC values. However, this may
also be impacted by histology as the three tumors with-
out an inverse correlation between voxel SUV and ADC
were small, well/moderately differentiated AdenoCAs.
There was not a significant correlation between MTV
and the voxel SUV/ADC relationship in SCCAs, even
though some of the SCCAs had small volumes (Fig. 3e).
Finally, we examined the prognostic potential of PET/
MRI metrics as an exploratory analysis in our patient co-
hort. This analysis did not separate patients by histology.
Only univariate analysis was performed given our small
patient cohort. Interestingly, when the imaging metrics
were stratified by their median, the Pearson correlation
coefficient of the voxel ADC vs. SUV comparison was
prognostic of DFS by Kaplan-Meier/log-rank analysis
(Table 3, Fig. 4). That is, tumors with a stronger inverse
correlation between voxel SUV and ADC had poorer
disease outcomes. The prognostic significance of this
marker was found retrospectively, and given the correl-
ation between MTV and the voxel SUV/ADC relation-
ship, MTV may be confounding the impact of the voxel
SUV/ADC correlation on DFS. This underscores that
while interesting, these results must be confirmed pro-
spectively in a larger patient cohort.
The primary limitation of this study is the small sam-
ple size and its retrospective nature. This likely explains
the variability seen between some of our results and the
results of some previous studies, many of which also
have small sample size. It is certainly possible that some
of the relationships reported here between PET and ADC
metrics may change or be refuted in a larger dataset. The
small number of patients also limited our statistical ana-
lysis. In particular, we did not correct for multiple testing,
nor did we perform a multivariate statistical analysis com-
paring imaging metrics to other known prognostic factors,
such as FIGO stage, lymph node involvement, and change
in tumor uptake on post-treatment [18F]FDG-PET. In
addition, our patient cohort is heterogeneous, and in-
cludes patients treated with definitive chemoradiation and
surgery, and cancers of a variety of grades, histologies, and
stages. The scanning protocols in this patient cohort were
also somewhat heterogeneous. Namely, a majority of pa-
tients received a PET/CT scan prior their PET/MR and
thus had a delayed PET/MR acquisition relative to tracer
injection. Finally, in this study, tumor volumes were de-
fined manually on the ADC images to encompass the
diffusion-restricted regions of tumor, and this approach
could be susceptible to bias. The results reported here
should therefore be viewed as hypothesis generating and
must be confirmed and validated in a larger prospective
patient cohort.
Nevertheless, the differences between histologies and
tumor grades in the relationship of voxel [18F]FDG-PET
SUV to ADC are interesting findings that warrant fur-
ther investigation. Further work will need to validate the
findings presented here and should also focus on defin-
ing the biologic and physiologic mechanisms underlying
the relationship between SUV and ADC, for example,
cellular density, proliferation, immunologic infiltrate,
and mutational status.
Conclusions
This work has demonstrated that, in our cervical cancer
patient cohort, voxel values of ADC and SUV are in-
versely correlated in all SCCAs, but their relationship in
adenocarcinomas is indeterminate. There is also a sig-
nificant difference in the voxel ADC/SUV correlation be-
tween poorly and well/moderately differentiated tumors.
Furthermore, we have shown that the correlation be-
tween voxel ADC and SUV values may have prognostic
significance, though this may be confounded by the cor-
relation between MTV and the voxel SUV/ADC rela-
tionship. These findings must be confirmed and
validated in a larger patient cohort, and future work
should also determine the biology underlying the rela-
tionship between imaging metrics reported here.
Additional file
Additional file 1: Figure S1. Comparison of the global tumor metrics
of SUVmean and ADCmean (a), SUVmean and ADCT/M (b), SUVT/M and
ADCmean (c), and SUVT/M and ADCT/M (d) for all tumors. There was a
significant inverse correlation between SUVmean and ADCmean and ADCT/M, but
no significant correlation between SUVT/M and either ADCmean or ADCT/M.
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When SCCAs and AdenoCAs are considered separately, there is no significant
correlation between SUVmean and ADCmean for either AdenoCAs (e) or
SCCAs (f).
Table S1. Univariate Cox proportional hazards analysis and log-rank analysis
for OS for the imaging metrics investigated. Variables were treated as categor-
ical, dichotomized by the median for each imaging metric. (DOCX 8404 kb)
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